Assistant Professor in Lymphoma @OSUHematology. @NUFeinbergMed alum. Interested in #lymsm #MedEd #WomenInMedicine #HemeSurvivorship. Views are my own.
Joined September 2014
- Tweets 487
- Following 253
- Followers 356
- Likes 479
19 Photos and videos
Audrey Sigmund retweeted
Jun 11
End of Methotrexate for CNS Prophylaxis in Diffuse Large B-Cell Lymphoma | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JCO…
6
60
133
10,207
Interested in #Hematology?🩸
Join the @ASH_hematology Horizons in Hematology Group—a FREE online community designed to engage, inform, and inspire medical students & junior residents exploring careers in the field🩺
Sign up here:
ashconnections.hematology.or…
56
Audrey Sigmund retweeted
May 31
Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial - The Lancet thelancet.com/journals/lance…
22
61
4,747
Audrey Sigmund retweeted
May 12
Prebiopsy steroids & diagnostic yield in DLBCL #lymsm
- 320 pts
- diagnostic yield unchanged w/ steroids (83% vs 81%)
- no association w/ dose or duration
- no delay in time to treatment
- FNA way less diagnostic than excisional/incisional
- Core needle 12% less likely to be diagnostic
Useful real-world data for pts needing steroids before diagnosis
jamanetwork.com/journals/jam…
22
56
4,029
Audrey Sigmund retweeted
Mar 24
🚨Just out in @BrJHaem
Hodgkin lymphoma's new era: choosing between Nivo-AVD and BrECADD
We compare and contrast HD21 & SWOG1826, attempting to be as neutral and objective as possible
Which would you choose?
onlinelibrary.wiley.com/doi/… #lymsm @mike_dickinson1
6
31
102
5,844
Audrey Sigmund retweeted
Imposter Syndrome, Burnout, and Maladaptive Perfectionism Among Oncology Professionals: A Global Cross-Sectional Study.
Read the full article. bit.ly/4d5cW3G
5
12
1,980
Audrey Sigmund retweeted
TOMORROW we’re launching our DLBCL webinar series!
Join @PallawiTorkaMD and Emily Ayers as they tackle treatment decisions in older patients — a conversation we all need in real-world practice.
Register at the link below and save your spot! us06web.zoom.us/webinar/regi…
2
8
14
906
Audrey Sigmund retweeted
Join the #BrighamBEI for Leadership in #MedEd, a new 4 part series for medical educators looking to build leadership skills, think strategically, and advance their careers. Kicks off April 8!
Register: bit.ly/BEI_Leadership
@BrighamFellows
@BrighamRadOnc
@harvardneuromds
1
4
310
Audrey Sigmund retweeted
Zanwar et al - POD24 in WM.
• 253 pts all Rx with 1L BR
• 5y PFS / OS 65% / 87%
• CXCR4 mutn worse prog (med PFS 3.3 v 8.8y
• POD24 (11%) assoc inf OS 71 v 86%
Not surprising but good to have data.
#lymsm
ashpublications.org/bloodadv…
4
20
1,382
Audrey Sigmund retweeted
18 Dec 2025
💬 Viewpoint: Mass abstract submissions in #MedEd have led to inflated metrics, less meaningful research, and misaligned incentives for trainees and institutions.
ja.ma/4qlJES1
ALT JAMA viewpoint article titled "Abstract Factory—Research Culture Harming Medical Education" by Samer Al Hadidi et al., published online December 18, 2025. The article discusses the impact of mass abstract submissions on medical education.
3
132
441
193,020
Audrey Sigmund retweeted
20 Dec 2025
Y Wang et al - ritux Maint after 1L BR in MCL
• 703 pts with ORR to 1L BR at 3mo post
• retrospect
• 56% R Mx, 44% no Mx (similar features)
• landmark analy: med EFS 49.9 mo with Mx, 29.7mo without, also OS benefit.
Confirms role of MxR in MCL
#lymsm
ashpublications.org/bloodadv…
2
19
48
4,110
Audrey Sigmund retweeted
7 Dec 2025
The L-THORs (Lymphoma Translational Health Outcomes Researchers) assemble at #ASH25, presenting work in patient-reported outcomes and time toxicity! 🎉 #lymsm cc @ASH_hematology
8
19
1,061
Audrey Sigmund retweeted
6 Dec 2025
Herrera et al - 3y FU SWG 1826
- BV-AVD vs Nivo-AVD 1L III/IV Hodgkin
- PFS benefit signif: 82% vs 91%
- High & low PFS benefit
- Particularly striking benefit older pfs (& adolescents)
- No myeloid malig in either arm
Fantastic data with this regimen #ASH25 #lymsm
1
36
87
6,511
Bedside clinical skills have been diminished by an overreliance on technology. A new Review Article presents educational strategies for reinvigorating the bedside encounter and shows how much can be learned from it.
Read the review “Strategies to Reinvigorate the Bedside Clinical Encounter,” the latest in the Medical Education series, by Brian T. Garibaldi, MD, MEHP, and Stephen W. Russell, MD, from @NUFeinbergMed and the University of Alabama at Birmingham (@UABNews): nej.md/4nUirnP
ALT Review Article | Medical Education Strategies to Reinvigorate the Bedside Clinical Encounter An illustration describing a scenario with a patient, a resident, and a medical educator
26
223
572
102,022
6 Nov 2025
RT @OncLive: Learn more about clinical outcomes with a treatment option for 3L DLBCL adult patients. Click here hubs.ly/Q03S3vC30 to…
2
Monitoring ctDNA in aggressive B-cell lymphoma: a prospective correlative study of ctDNA kinetics and PET-CT metrics | Blood Advances | American Society of Hematology ashpublications.org/bloodadv…
7
21
1,738
Audrey Sigmund retweeted
27 Oct 2025
Cell-Of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B Cell Lymphoma aacrjournals.org/clincancerr…
16
48
4,446
Audrey Sigmund retweeted
26 Oct 2025
Optimising treatment strategies in older patients with mantle cell lymphoma - The Lancet thelancet.com/journals/lance…
13
40
3,684
Audrey Sigmund retweeted
9 Oct 2025
Treatment of relapsed and refractory follicular lymphoma: which treatment for which patient for which line of therapy? ashpublications.org/blood/ar…
Wonderful to work with Dr Laurie Sehn on this review highlighting our approach to relapsed FL #lymsm @BloodPortfolio @WilmotCancer
15
56
7,782
Audrey Sigmund retweeted
16 Oct 2025
Population-Wide Introduction of Dose-Adjusted EPOCH-R In High-grade B-cell Lymphoma with MYC/BCL2 Rearrangements, DLBCL Morphology | Blood Advances | American Society of Hematology ashpublications.org/bloodadv…
16
61
9,817